Current research into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing significant effects in managing obesity and related second-type disease. Animal data suggest a distinct process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/